COMP <GO>
BBIO vs ASND // RSI-14 & 200D SMA MOMENTUM
BridgeBio Pharma Inc. (NASDAQ) VS. Ascendis Pharma A/S Ordinary Share (NASDAQ) • 15-METRIC TALLY: BBIO 3
— ASND 8
▲ RSI-14 & 200D SMA MOMENTUM LEADER: BBIO
LAST: $75.00 (+0.06%) • MKT CAP: $14.60B
rsi-technicals
63.9
LAST: $248.98 (-0.91%) • MKT CAP: $16.55B
rsi-technicals
63.3
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BBIO VS. ASND)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BBIO | ASND | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 95.80% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 9.90% | -44.90 | ASND | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 21.0x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.23% | 2.21% | -5.44 | ASND | /fcf-yield <GO> |
| Operating Margin | -60.00% | 13.90% | -73.90 | ASND | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 10.90% | -70.90 | ASND | /net-margins <GO> |
| Revenue Growth (YoY) | 126.30% | 12.10% | +114.20 | BBIO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 3.74 | -3.29 | ASND | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | ASND | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 63.9 | 63.3 | +0.60 | BBIO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 0.98 | +0.02 | BBIO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 33.0x | 27.6x | +5.40 | ASND | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $14.60B | $16.55B | -$1.95B | ASND | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BBIO REV | ASND REV | BBIO GROSS % | ASND GROSS % | BBIO FCF | ASND FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $502.1M | — | 95.8% | — | -$447.0M | — |
| FY 2024 | $221.9M | — | 98.3% | — | -$521.7M | — |
| FY 2023 | $9.3M | — | — | — | -$528.1M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BBIO // BETA 1.00
ASND // BETA 0.98